Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORTEN omalizumab withdrawal in well-controlled severe allergic asthma
2024-513427-17-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omalizumab in allergic asthma (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Number of asthma exacerbations in the year following randomization. Planned start May 2021; status: authorised.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2024-513427-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513427-17-00.